서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 17 of 17

Issue DateTitle / Author(s) / CitationFileAltmetrics
2003-09
Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci

Kim, SH; Park, WB; Lee, KD; Kang, CI; Kim, HB; Oh, MD; Kim, EC; Choe, KW

Clinical Infectious Diseases, Vol.37 No.6, pp.794-799

DOI
2004-09
Bloodstream infections caused by Enterobacter species: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome

Kang, CI; Kim, SH; Park, WB; Lee, KD; Kim, HB; Oh, MD; Kim, EC; Choe, KW

Clinical Infectious Diseases, Vol.39 No.6, pp.812-818

DOI
2005-09
Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: Undiluted and diluted lancy-vaxina vaccine in a single-blind, randomized, prospective trial

Kim, SH; Yeo, SG; Jang, HC; Park, WB; Lee, CS; Lee, KD; Kim, HB; Kim, NJ; Kim, YT; Jee, Y; Cho, HW; Oh, M; Choe, KW

Journal of Infectious Diseases, Vol.192 No.6, pp.1066-1070

DOI
2006-08
Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus
DOI
2009-02
Should HLA-B*5701 Screening Be Performed in Every Ethnic Group before Starting Abacavir?
DOI
2010-07
Genetic Factors Influencing Severe Atazanavir-Associated Hyperbilirubinemia in a Population with Low UDP-Glucuronosyltransferase 1A1*28 Allele Frequency
DOI
2012-10
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-12
Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors
DOI
2021-07
Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
DOI
2021-08
Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability
DOI
2021-09
Persistence of Neutralizing Antibody Response up to 1 Year after Asymptomatic or Symptomatic SARS-CoV-2 Infection
DOI
2021-11
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019
DOI
2022-06
Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus
DOI
2022-09
Longitudinal Analysis of Memory T-Cell Responses in Survivors of Middle East Respiratory Syndrome
DOI
2022-09
Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection
DOI
2023-04
Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection (vol 224, jiab159, 2021)
DOI
1